about
Severe serotonin syndrome induced by mirtazapine monotherapy.Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.Monoclonal antibodies in the treatment of advanced colorectal cancer.Aurora kinase family: a new target for anticancer drug.Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.The role of salvage treatment in advanced colorectal cancer.Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.New approaches and targets in advanced colorectal cancer.Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.Right-left or midgut-hindgut?A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.K-Ras mutation status as a predictive biomarker in metastatic colorectal cancerCetuximab and Chemotherapy for Patients with Unresectable CRC Liver Metastasis: Are We Changing the Natural Course of the Disease?Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors
P50
Q34579618-B2B7A9B0-3D85-4575-A6E7-FE92D8EBCCC0Q34975423-14DAE7A3-B16C-4062-A46E-A881D3753A98Q36412351-0B990C82-AC70-4600-89AA-5795B37E873DQ36879172-B5615AEF-B28C-479C-9354-FC94C884AA0FQ36991607-42184863-345B-402F-8E1D-F53E0CC09E23Q37185337-8F6A522A-02AA-4776-903A-C442C31D6C2EQ37270038-00FFDD17-53F9-48EF-ADA9-9589E13E2AAEQ37314824-C063618F-7A75-4714-BFAE-DC2C70CF1C08Q37343930-3B6850BE-3EF6-486B-8708-B2F2F389DFB6Q37408698-C02B36ED-E97C-4E1E-8873-C1BC4F714C9BQ37468353-B773CBBA-920D-4070-B41D-FE83550A0466Q39925893-700A522C-7571-4723-80DE-7117B82042AAQ43184357-DBF24371-CF63-4484-9080-B2EC4F814512Q43272429-07747EEC-F9CA-4F68-AEED-8E4EA717785FQ46708758-C1FD317E-B30B-41B1-AC4B-952C07D32818Q48320672-E9CEC27A-47C5-4081-BD2E-05E66B07DA32Q49842960-40D78568-B129-42DF-8914-E4B5B7AF48C0Q54600318-B2A72941-E5CA-472D-B208-D02A3B06081AQ58614826-D065B442-A2D5-44B6-820E-9ED1F9B40676Q58614853-AD616FD0-A723-41B9-9501-FD8EA2000C3DQ58614929-FFF04488-92A3-4DDC-8AF3-40F1C36E15E8
P50
description
researcher
@en
wetenschapper
@nl
name
Francisco J Ramos
@en
Francisco J Ramos
@nl
type
label
Francisco J Ramos
@en
Francisco J Ramos
@nl
prefLabel
Francisco J Ramos
@en
Francisco J Ramos
@nl
P108
P106
P108
P21
P31
P496
0000-0002-0918-5895